Literature DB >> 15985316

Induction of CD8+ T cell responses by Yersinia vaccine carrier strains.

Carolin A Wiedig1, Uwe Kramer, Sara Garbom, Hans Wolf-Watz, Ingo B Autenrieth.   

Abstract

Yersinia enterocolitica employs a type III secretion system (TTSS) to target virulence factors (e.g. YopE) into the cytosol of the host cells. We utilized the TTSS to introduce a recombinant antigen directly into the cytosol of host cells and to investigate the potential of Y. enterocolitica and Y. pseudotuberculosis as live carrier for vaccines. The model antigen ovalbumin (Ova) was fused to defined secretion or translocation domains of the Yersinia effector protein YopE and introduced into attenuated mutant strains of Y. enterocolitica and Y. pseudotuberculosis. In vitro experiments showed secretion and translocation of YopE-Ova hybrid proteins into host cells. To investigate the resulting immune responses, mice expressing transgenic Ova-specific T cell receptors were used. Both Y. enterocolitica and Y. pseudotuberculosis mutants induced efficaciously Ova-specific CD8+ T cell responses. The translocation domain of YopE was required for induction of CD8+ T cell responses in vivo, but not for T cell responses induced in vitro. The in vivo frequency of Ova-specific splenic T cells was up to six-fold higher in mice immunized with YopE-Ova-translocating Y. enterocolitica/Y. pseudotuberculosis mutants than in control mice. The Ova-specific T cells were shown to produce high amounts of IFN-gamma. We did not observe significant Ova-specific CD4+ T cell or antibody responses upon vaccination with either of the strains. In conclusion, Yersinia live carrier vaccine strains are suitable to target antigens into the MHC class I pathway and stimulate CD8+ T cell responses and thus, might be useful in vaccine approaches against intracellular pathogens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15985316     DOI: 10.1016/j.vaccine.2005.05.027

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis.

Authors:  Yue Zhang; Patricio Mena; Galina Romanov; Jr-Shiuan Lin; Stephen T Smiley; James B Bliska
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

2.  The Yersinia enterocolitica invasin protein promotes major histocompatibility complex class I- and class II-restricted T-cell responses.

Authors:  O T Bühler; C A Wiedig; Y Schmid; G A Grassl; E Bohn; I B Autenrieth
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

3.  Oral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plague.

Authors:  Wei Sun; Shilpa Sanapala; Hannah Rahav; Roy Curtiss
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

4.  LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.

Authors:  Wei Sun; Shilpa Sanapala; Jeremy C Henderson; Shandiin Sam; Joseph Olinzock; M Stephen Trent; Roy Curtiss
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

5.  Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague.

Authors:  Jr-Shiuan Lin; Frank M Szaba; Lawrence W Kummer; Brett A Chromy; Stephen T Smiley
Journal:  J Immunol       Date:  2011-06-08       Impact factor: 5.422

6.  YopJ-promoted cytotoxicity and systemic colonization are associated with high levels of murine interleukin-18, gamma interferon, and neutrophils in a live vaccine model of Yersinia pseudotuberculosis infection.

Authors:  Yue Zhang; James B Bliska
Journal:  Infect Immun       Date:  2010-03-15       Impact factor: 3.441

7.  Effector CD8+ T cells are generated in response to an immunodominant epitope in type III effector YopE during primary Yersinia pseudotuberculosis infection.

Authors:  Yue Zhang; Patricio Mena; Galina Romanov; James B Bliska
Journal:  Infect Immun       Date:  2014-05-05       Impact factor: 3.441

8.  High-throughput identification of new protective antigens from a Yersinia pestis live vaccine by enzyme-linked immunospot assay.

Authors:  Bei Li; Lei Zhou; JingYu Guo; Xiaoyi Wang; Bin Ni; Yuehua Ke; Ziwen Zhu; Zhaobiao Guo; Ruifu Yang
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

9.  CD8(+) T cells specific to a single Yersinia pseudotuberculosis epitope restrict bacterial replication in the liver but fail to provide sterilizing immunity.

Authors:  Haiqian Shen; Norberto Gonzalez-Juarbe; Krystle Blanchette; Gregory Crimmins; Molly A Bergman; Ralph R Isberg; Carlos J Orihuela; Peter H Dube
Journal:  Infect Genet Evol       Date:  2016-06-04       Impact factor: 3.342

10.  Yersinia enterocolitica targets cells of the innate and adaptive immune system by injection of Yops in a mouse infection model.

Authors:  Martin Köberle; Annegret Klein-Günther; Monika Schütz; Michaela Fritz; Susanne Berchtold; Eva Tolosa; Ingo B Autenrieth; Erwin Bohn
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.